Clinical trials: Schizophrenic Disorders
Schizophrenia
Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese and Non-Japanese Female Subjects
This study is being conducted to evaluate the safety and tolerability of ascending multiple oral doses of SCA-136 adminstered to healthy Japanese and non-Japanese female subjects.
- Trial name
- NCT00458107
- Testing
- SCA-136
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Schizophrenia
A Study Comparing the Efficacy and Tolerability of Ziprasidone vs. Clozapine for the Treatment of Schizophrenia in Patients Who Continue to Have Symptoms on or Cannot Tolerate Other Antipsychotic Drugs
The purpose of this study is to compare the efficacy and safety of ziprasidone and clozapine in schizophrenic patients who are resistant and/or intolerant to antipsychotic treatment
- Trial name
- MOZART (NCT00649844)
- Testing
- Clozapine, Ziprasidone
- Where
- 22 sites in Italy
- Volunteers
- 147 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia
A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia
This is a multicenter, open-label, adaptive, repeat-dose study to evaluate the safety, tolerability, and pharmacokinetics of iloperidone long-acting injection (LAI) in patients with schizophrenia.
- Trial name
- NCT04712734
- Testing
- Iloperidone
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Vanda Pharmaceuticals
Schizophrenia
Medial-prefrontal Enhancement During Schizophrenia Systems Imaging
This randomized controlled trial in healthy controls (HC) and patients with schizophrenia (SZ) aims to examine 1) the underlying cognitive and neural cause of self-agency deficits in SZ; 2) the responsiveness to a novel navigated…
- Trial name
- MESSI (NCT04807530)
- Testing
- TMS
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Schizophrenia
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)
This is a Phase 3, multicenter, 56-week, outpatient, open-label (OL) study to evaluate the long-term safety, tolerability, and efficacy of KarXT in de novo subjects with Diagnostic and Statistical Manual-Fifth Edition (DSM-5)…
- Trial name
- NCT04820309
- Testing
- Xanomeline and Trospium Chloride Capsules
- Where
- 117 sites in United States, Puerto Rico
- Volunteers
- 566 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Schizoaffective Disorder, Schizophrenia
Long-Acting Injectable Risperidone in the Treatment of Schizophrenia
In the proposed study 450 veterans with a primary diagnosis of schizophrenia who had at least one psychiatric hospitalization for schizophrenia in the previous 2 years would be randomly assigned at 16 VA medical centers to…
- Trial name
- NCT00132314
- Testing
- IM risperidone, oral antipsychotic medication
- Where
- 19 sites in United States
- Volunteers
- 382 people
- Sponsor
- US Department of Veterans Affairs
Schizophrenia, Schizophreniform Disorder
A German Multicenter Study on Toxoplasma Gondii in First-episode Schizophrenia
Environmental risk factors for the development of schizophrenia include infections during the perinatal period or later in life with Toxoplasma gondii (TG) being one of the candidate agents.
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
- Trial name
- NCT00686400
- Testing
- TAU = treatment as usual
- Where
- 3 sites in Germany
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Martin-Luther-Universität Halle-Wittenberg
Clinical High Risk for Psychosis, Ultra High Risk for Psychosis
Endocannabinoid Activity Remodulation for Psychosis Liability in Youth
Clinical High-Risk (CHR) for Psychosis is characterized by the occurrence of unusual stressful experiences (attenuated psychotic symptoms, APS), anxious symptoms, psychological distress, and substantial impairment of the…
- Conditions
- Clinical High Risk for Psychosis, Ultra High Risk for Psychosis, Attenuated Psychotic Symptoms
- Trial name
- EARLY (NCT06037993)
- Testing
- Ultra-micronized Palmitoylethanolamide (PEA)
- Where
- 2 sites in Italy
- Volunteers
- 20 people
- Sponsor
- University of Udine
Schizophrenia, Schizoaffective Disorder
A Definitive Estrogen Patch Study (ADEPT)
OBJECTIVE: To test the use of adjunctive estrogen in a 8 week, three-arm, double-blind, placebo-controlled study in the treatment of psychotic symptoms in women with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder(Not in Manic Phase)
- Trial name
- NCT00357006
- Testing
- Estradiol
- Where
- Australia
- Volunteers
- 180 people
- Sponsor
- The Alfred
Schizophrenia, Undifferentiated Type
Comparison of the Effects of Aripiprazole and Risperidone on the Pattern of Brain Activation in Schizophrenic Patients
After an initial screening visit, including an assessment of psychiatric disorders, patients stabilized on antipsychotic medication (aripiprazole or risperidone) for at least 6 weeks and control subjects will undergo an…
- Trial name
- NCT01109147
- Testing
- Imagery, pharmacogenetic sampling
- Where
- 2 sites in France
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Qualissima
Schizophrenia
Cerebellar rTMS for the Treatment of Schizophrenic Patients
The primary aim of this protocol is to determine whether the use of repetitive transcranial magnetic stimulation (rTMS) over vermis of the cerebellum may be safe and therapeutically effective in patients with schizophrenia.
- Trial name
- NCT01072617
- Testing
- Transcranial magnetic stimulation via MagPro x100 device
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Schizophrenia
rTMS for Auditory Hallucinations Guided by Magnetoencephalography
rTMS and MEG for auditory hallucinations via self controlled clinical trials. Repetitive transcranial magnetic stimulation (rTMS) can increase or decrease cortical excitability in patients with psychosis (such as schizophrenia).
- Trial name
- NCT05598450
- Testing
- rTMS and MEG for auditory hallucinations via self controlled clinical trials
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Mental Health Center
Psychosis
Cognitive Behavioural Therapy-Informed Groups for Psychosis
This is a feasibility study of cognitive behavioural therapy-informed groups for psychiatric inpatients with positive symptoms of psychosis.
- Trial name
- CBTp (NCT05584215)
- Testing
- Cognitive Behavioural Therapy for Psychosis Groups
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Schizophrenia, Schizoaffective
An Open Trial of Cysteamine Treatment in Schizophrenia
The purpose of this study is to determine the tolerability of the medication cysteamine bitartrate on schizophrenia patients and to evaluate the effect of the medication on the symptoms of schizophrenia.
- Trial name
- NCT01139125
- Testing
- (Cystagon) Cysteamine Bitartrate
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Augusta University
Schizophrenia, Bipolar Disorder
Mobile Self-Tracking of Mental Health
Serious mental illnesses require years of monitoring and adjustments in treatment. Stress, substance abuse or reduced medication adherence cause rapid worsening of symptoms, with consequences that include job loss, homelessness…
- Conditions
- Schizophrenia, Bipolar Disorder, Schizoaffective Disorder, Post-traumatic Stress Disorder
- Trial name
- NCT05023252
- Testing
- mobile application
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- VA Office of Research and Development
Schizophrenia Spectrum Disorder
Transcranial Magnetic Stimulation (TMS) for Negative Symptoms in Schizophrenia Spectrum Disorders
The purpose of this study is to determine if repetitive transcranial magnetic stimulation (rTMS) applied to angular gyrus (AG) will improve negative symptoms and/or other psychosis symptoms in schizophrenia spectrum disorders…
- Trial name
- NCT07290738
- Testing
- TMS
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The University of Texas Health Science Center, Houston
Schizophrenia
A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study…
- Trial name
- NCT07459647
- Testing
- ML-007C-MA
- Where
- 45 sites in United States
- Volunteers
- 500 people
- Sponsor
- MapLight Therapeutics
Prodromal Schizophrenia
Effects of NAC on Symptoms of CHR Patients
Schizophrenia is a chronic debilitating psychotic disorder. Identifying persons with "clinical high-risk" (CHR) symptoms, which are like those of schizophrenia but less severe, and providing psychiatric care to these individuals…
- Trial name
- NCT05142735
- Testing
- N-Acetylcysteine
- Where
- Canada
- Volunteers
- 90 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia
Valproate in Late Life Schizophrenia
The purpose of this research study is to analyze the effectiveness and tolerability of a medication, valproate ( Depakote and Depakote ER), in individuals age 50 years and older who have schizophrenia.
- Trial name
- NCT00194025
- Testing
- Valproate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University Hospitals Cleveland Medical Center
Schizophrenia Disorders
Investigating the Effect of Diroximel Fumarate on Glutathione in Schizophrenia
Schizophrenia is a condition that causes symptoms like delusions, hallucinations, reduced motivation and muddled thinking. It is a common, severe and disabling psychiatric illness affecting about 1/100 (1%) of people.
- Trial name
- FORTUNE (NCT06957808)
- Testing
- Diroximel fumarate (DRF)
- Where
- 3 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- King's College London